Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

Peter Martin, Zhengming Chen, Bruce D. Cheson, Katherine S. Robinson, Michael Williams, Saurabh A. Rajguru, Jonathan W. Friedberg, Richard H. van der Jagt, Ann S. LaCasce, Robin Joyce, Kristen N. Ganjoo, Nancy L. Bartlett, Bernard Lemieux, Vanderwalde Ari, Jordan Herst, Jeffrey Szer, Michael H. Bar, Fernando Cabanillas, Anthony J. Dodds, Paul G. Montgomery & 4 others Bryn Pressnail, Tricia Ellis, Mitchell R. Smith, John P. Leonard

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39–84), and patients had received a median of 3 prior therapies. The histologies included grades 1–2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Original languageEnglish (US)
Pages (from-to)250-256
Number of pages7
JournalBritish Journal of Haematology
Volume178
Issue number2
DOIs
StatePublished - Jul 1 2017

Fingerprint

Non-Hodgkin's Lymphoma
Stem Cells
Neoplasms
Lymphoma
Mantle-Cell Lymphoma
Follicular Lymphoma
Myelodysplastic Syndromes
B-Cell Chronic Lymphocytic Leukemia
Patient Safety
Bendamustine Hydrochloride
Acute Myeloid Leukemia
Disease-Free Survival
Histology
History
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. / Martin, Peter; Chen, Zhengming; Cheson, Bruce D.; Robinson, Katherine S.; Williams, Michael; Rajguru, Saurabh A.; Friedberg, Jonathan W.; van der Jagt, Richard H.; LaCasce, Ann S.; Joyce, Robin; Ganjoo, Kristen N.; Bartlett, Nancy L.; Lemieux, Bernard; Ari, Vanderwalde; Herst, Jordan; Szer, Jeffrey; Bar, Michael H.; Cabanillas, Fernando; Dodds, Anthony J.; Montgomery, Paul G.; Pressnail, Bryn; Ellis, Tricia; Smith, Mitchell R.; Leonard, John P.

In: British Journal of Haematology, Vol. 178, No. 2, 01.07.2017, p. 250-256.

Research output: Contribution to journalArticle

Martin, P, Chen, Z, Cheson, BD, Robinson, KS, Williams, M, Rajguru, SA, Friedberg, JW, van der Jagt, RH, LaCasce, AS, Joyce, R, Ganjoo, KN, Bartlett, NL, Lemieux, B, Ari, V, Herst, J, Szer, J, Bar, MH, Cabanillas, F, Dodds, AJ, Montgomery, PG, Pressnail, B, Ellis, T, Smith, MR & Leonard, JP 2017, 'Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma', British Journal of Haematology, vol. 178, no. 2, pp. 250-256. https://doi.org/10.1111/bjh.14667
Martin, Peter ; Chen, Zhengming ; Cheson, Bruce D. ; Robinson, Katherine S. ; Williams, Michael ; Rajguru, Saurabh A. ; Friedberg, Jonathan W. ; van der Jagt, Richard H. ; LaCasce, Ann S. ; Joyce, Robin ; Ganjoo, Kristen N. ; Bartlett, Nancy L. ; Lemieux, Bernard ; Ari, Vanderwalde ; Herst, Jordan ; Szer, Jeffrey ; Bar, Michael H. ; Cabanillas, Fernando ; Dodds, Anthony J. ; Montgomery, Paul G. ; Pressnail, Bryn ; Ellis, Tricia ; Smith, Mitchell R. ; Leonard, John P. / Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. In: British Journal of Haematology. 2017 ; Vol. 178, No. 2. pp. 250-256.
@article{97d1f6c770cd45b9b579b9e4dfb5bd39,
title = "Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma",
abstract = "Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39–84), and patients had received a median of 3 prior therapies. The histologies included grades 1–2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.",
author = "Peter Martin and Zhengming Chen and Cheson, {Bruce D.} and Robinson, {Katherine S.} and Michael Williams and Rajguru, {Saurabh A.} and Friedberg, {Jonathan W.} and {van der Jagt}, {Richard H.} and LaCasce, {Ann S.} and Robin Joyce and Ganjoo, {Kristen N.} and Bartlett, {Nancy L.} and Bernard Lemieux and Vanderwalde Ari and Jordan Herst and Jeffrey Szer and Bar, {Michael H.} and Fernando Cabanillas and Dodds, {Anthony J.} and Montgomery, {Paul G.} and Bryn Pressnail and Tricia Ellis and Smith, {Mitchell R.} and Leonard, {John P.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/bjh.14667",
language = "English (US)",
volume = "178",
pages = "250--256",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

AU - Martin, Peter

AU - Chen, Zhengming

AU - Cheson, Bruce D.

AU - Robinson, Katherine S.

AU - Williams, Michael

AU - Rajguru, Saurabh A.

AU - Friedberg, Jonathan W.

AU - van der Jagt, Richard H.

AU - LaCasce, Ann S.

AU - Joyce, Robin

AU - Ganjoo, Kristen N.

AU - Bartlett, Nancy L.

AU - Lemieux, Bernard

AU - Ari, Vanderwalde

AU - Herst, Jordan

AU - Szer, Jeffrey

AU - Bar, Michael H.

AU - Cabanillas, Fernando

AU - Dodds, Anthony J.

AU - Montgomery, Paul G.

AU - Pressnail, Bryn

AU - Ellis, Tricia

AU - Smith, Mitchell R.

AU - Leonard, John P.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39–84), and patients had received a median of 3 prior therapies. The histologies included grades 1–2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.

AB - Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39–84), and patients had received a median of 3 prior therapies. The histologies included grades 1–2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=85017563370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017563370&partnerID=8YFLogxK

U2 - 10.1111/bjh.14667

DO - 10.1111/bjh.14667

M3 - Article

VL - 178

SP - 250

EP - 256

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -